MARKET

MTVA

MTVA

MetaVia Inc
NASDAQ
1.640
-0.020
-1.20%
After Hours: 1.651 +0.011 +0.64% 19:56 02/13 EST
OPEN
1.825
PREV CLOSE
1.660
HIGH
1.960
LOW
1.540
VOLUME
2.40M
TURNOVER
--
52 WEEK HIGH
23.10
52 WEEK LOW
1.540
MARKET CAP
5.26M
P/E (TTM)
-0.1182
1D
5D
1M
3M
1Y
5Y
1D
MetaVia Secures Dozens Of Patents Through 2041 For Obesity Drug
Benzinga · 10h ago
Vanguard Total Stock Market ETF (VTI) Daily Update—2/13/26
TipRanks · 11h ago
BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Mohawk
Reuters · 12h ago
BUZZ-U.S. STOCKS ON THE MOVE-Opus Genetics, MetaVia, Enbridge 
Reuters · 13h ago
BUZZ-MetaVia rises after securing global patent protection for obesity drug
Reuters · 14h ago
MetaVia creates intellectual property portfolio supporting DA-1726
TipRanks · 14h ago
MetaVia Announces Global IP Portfolio Supporting DA-1726, Dual OXM Analog Agonist That Functions As GLP1R And GCGR, For Treatment Of Obesity And Related Metabolic Disorders
Benzinga · 14h ago
METAVIA BUILDS COMPREHENSIVE GLOBAL PATENT PROTECTION FOR DA-1726, SECURING EXCLUSIVE RIGHTS TO NOVEL OBESITY AND METABOLIC THERAPY THROUGH 2041
Reuters · 14h ago
More
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.

Webull offers MetaVia Inc stock information, including NASDAQ: MTVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MTVA stock methods without spending real money on the virtual paper trading platform.